Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Generic Name: Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Indication: 用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；

2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；

3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；

4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；

5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Clinical Trials

The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion

Phase 1

Conditions: Chronic Hepatitis B

Interventions: Drug: Drug
Drug: GM-CSF control

First Posted Date: 2013-06-17

Last Posted Date: 2013-07-24

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 40

Registration Number: NCT01878565

Locations: 🇨🇳
Beijing 302 Hospital, Beijing, China

Therapy for Children With Advanced Stage Neuroblastoma

Phase 2

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: cyclophosphamide
Drug: topotecan
Biological: hu14.18K322A
Procedure: peripheral blood stem cell harvest
Procedure: surgical resection
Drug: cisplatin
Drug: etoposide
Drug: doxorubicin
Drug: vincristine
Drug: busulfan
Drug: melphalan
Biological: peripheral blood stem cell transplantation
Biological: natural killer cell infusion
Radiation: radiation therapy
Biological: GM-CSF
Biological: G-CSF
Drug: mesna
Drug: levetiracetam
Biological: interleukin-2
Drug: Isotretinoin
Device: CliniMACS

First Posted Date: 2013-05-20

Last Posted Date: 2025-03-10

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 153

Registration Number: NCT01857934

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Not Applicable

Conditions: Multiple Myeloma

Interventions: Biological: Galinpepimut-S
Biological: GM-CSF
Other: Montanide
Drug: lenalidomide
Drug: bortezomib

First Posted Date: 2013-04-09

Last Posted Date: 2020-01-10

Lead Sponsor: Sellas Life Sciences Group

Target Recruit Count: 22

Registration Number: NCT01827137

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Use of GM-CSF Supplemented IVF Medium in Patients With Recurrent Implantation Failure

Phase 4

Completed

Conditions: Infertility

Interventions: Drug: GM-CSF medium
Drug: CONTROL

First Posted Date: 2012-10-31

Last Posted Date: 2016-04-27

Lead Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy

Target Recruit Count: 100

Registration Number: NCT01718210

Locations: 🇮🇹
Villa Salaria Fisiopatologia Riproduzione, Rome, Italy

Use of GM-CSF Treatment in Recurrent Implantation Failure

Phase 3

Conditions: Women With Recurrent Implantation Failure in IVF

Interventions: Drug: CONTROL
Drug: GM-CSF group

First Posted Date: 2012-10-29

Last Posted Date: 2022-07-20

Lead Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy

Target Recruit Count: 140

Registration Number: NCT01715974

Locations: 🇮🇹
Cerm-Hungaria, Rome, Italy

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Herceptin
Drug: NeuVax vaccine
Drug: GM-CSF

First Posted Date: 2012-04-04

Last Posted Date: 2020-12-02

Lead Sponsor: George E. Peoples

Target Recruit Count: 275

Registration Number: NCT01570036

Locations: 🇺🇸
University of Miami, Plantation, Florida, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸
Texas Oncology (Cancer Care Centers of South Texas), San Antonio, Texas, United States

and more 23 locations

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Azacytidine
Drug: GM-CSF

First Posted Date: 2012-03-02

Last Posted Date: 2014-04-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT01542684

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Ipilimumab
Drug: GM-CSF

First Posted Date: 2012-02-10

Last Posted Date: 2015-10-05

Lead Sponsor: Lawrence Fong

Registration Number: NCT01530984

Locations: 🇺🇸
University of California, San Francisco, California, United States

GM-CSF for Immunomodulation Following Trauma (GIFT) Study

Phase 4

Completed

Conditions: Critical Injury (Trauma) in Children

Interventions: Drug: GM-CSF

First Posted Date: 2011-12-20

Last Posted Date: 2023-09-13

Lead Sponsor: Mark Hall

Target Recruit Count: 108

Registration Number: NCT01495637

Locations: 🇺🇸
Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 5 locations

The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia

Not Applicable

Completed

Conditions: Endotoxemia
Inflammation
Multi Organ Dysfunction Syndrome
Sepsis

Interventions: Other: E.coli endotoxin
Drug: GM-CSF
Drug: IFN-Y

First Posted Date: 2011-06-16

Last Posted Date: 2013-06-27

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 18

Registration Number: NCT01374711

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy